REFERENCES
1. Abrams M, Magun E, DeFilippis EM. Considerations for specific cardiomyopathies during pregnancy. Curr Opin Cardiol. 2023;38:233-40.
2. Iorgoveanu C, Zaghloul A, Ashwath M. Peripartum cardiomyopathy: a review. Heart Fail Rev. 2021;26:1287-96.
3. Satti DI, Choi E, Patel HP, et al. Cardiomyopathies in pregnancy: trends and clinical outcomes in delivery hospitalizations in the United States (2005-2020). Curr Probl Cardiol. 2024;49:102855.
4. Ricke-Hoch M, Pfeffer TJ, Hilfiker-Kleiner D. Peripartum cardiomyopathy: basic mechanisms and hope for new therapies. Cardiovasc Res. 2020;116:520-31.
5. Briller J, Vaught AJ. Cardiomyopathies in pregnancy: etiologies and management strategies. Clin Obstet Gynecol. 2020;63:893-909.
7. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur Heart J. 2023;44:3503-626.
8. Mehta LS, Warnes CA, Bradley E, et al; American Heart Association Council on Clinical Cardiology; Council on Arteriosclerosis. Cardiovascular considerations in caring for pregnant patients: a scientific statement from the American Heart Association. Circulation. 2020;141:e884-903.
9. DeFilippis EM, Haythe JH, Walsh MN, Kittleson MM. Intersection of heart failure and pregnancy: beyond peripartum cardiomyopathy. Circ Heart Fail. 2021;14:e008223.
10. Lewey J, Levine LD, Elovitz MA, Irizarry OC, Arany Z. Importance of early diagnosis in peripartum cardiomyopathy. Hypertension. 2020;75:91-7.
11. Sliwa K, Petrie MC, van der Meer P, et al. Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. Eur Heart J. 2020;41:3787-97.
12. Demakis JG, Rahimtoola SH, Sutton GC, et al. Natural course of peripartum cardiomyopathy. Circulation. 1971;44:1053-61.
13. Bauersachs J, König T, van der Meer P, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the heart failure association of the European Society of Cardiology study group on peripartum cardiomyopathy. Eur J Heart Fail. 2019;21:827-43.
14. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology working group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12:767-78.
15. Kryczka KE, Demkow M, Dzielinska Z. Peripartum cardiomyopathy - a cardiovascular disease in pregnancy and puerperium. The actual state of knowledge, challenges, and perspectives. Ginekol Pol. 2021;92:147-52.
16. Isezuo SA, Abubakar SA. Epidemiologic profile of peripartum cardiomyopathy in a tertiary care hospital. Ethn Dis. 2007;17:228-33.Available from: .
17. Kolte D, Khera S, Aronow WS, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J Am Heart Assoc. 2014;3:e001056.
18. Spracklen TF, Chakafana G, Schwartz PJ, et al. Genetics of peripartum cardiomyopathy: current knowledge, future directions and clinical implications. Genes. 2021;12:103.
19. Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:207-21.
20. Putra ICS, Irianto CB, Raffaello WM, Suciadi LP, Prameswari HS. Pre-pregnancy obesity and the risk of peripartum cardiomyopathy: a systematic review and meta-analysis. Indian Heart J. 2022;74:235-8.
21. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational research programme in conjunction with the heart failure association of the European Society of Cardiology study group on PPCM. Eur J Heart Fail. 2017;19:1131-41.
22. Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: national heart, lung, and blood institute and office of rare diseases (national institutes of health) workshop recommendations and review. JAMA. 2000;283:1183-8.
23. Anderson JL, Horne BD. Birthing the genetics of peripartum cardiomyopathy. Circulation. 2010;121:2157-9.
24. Bhattacharyya A, Basra SS, Sen P, Kar B. Peripartum cardiomyopathy: a review. Tex Heart Inst J. ;2012, 39:8-16.
25. Patten IS, Rana S, Shahul S, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012;485:333-8.
26. Walenta K, Schwarz V, Schirmer SH, et al. Circulating microparticles as indicators of peripartum cardiomyopathy. Eur Heart J. 2012;33:1469-79.
27. Ware JS, Li J, Mazaika E, et al; IMAC-2 and IPAC Investigators. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med. 2016;374:233-41.
28. Hinson JT, Campbell SG. TTN truncation variants produce sarcomere-integrating proteins of uncertain functional significance. J Clin Invest. 2024;134:e175206.
29. Goli R, Li J, Brandimarto J, et al; IMAC-2 and IPAC Investigators. Genetic and phenotypic landscape of peripartum cardiomyopathy. Circulation. 2021;143:1852-62.
30. Godinho R, Nowacka A, Bhuiyan Z, et al. Two years transplant-free survival after LVAD explantation in a titin truncating variant carrier with peripartum cardiomyopathy and cardiogenic shock. Circ Heart Fail. 2025;:e012079.
31. Morales A, Painter T, Li R, et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation. 2010;121:2176-82.
32. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2022;79:e263-421.
33. Kryczka KE, Demkow M, Dzielińska Z. Biomarkers in peripartum cardiomyopathy-what we know and what is still to be found. Biomolecules. 2024;14:103.
34. Haghikia A, Kaya Z, Schwab J, et al. Evidence of autoantibodies against cardiac troponin I and sarcomeric myosin in peripartum cardiomyopathy. Basic Res Cardiol. 2015;110:60.
35. Liu J, Wang Y, Chen M, et al. The correlation between peripartum cardiomyopathy and autoantibodies against cardiovascular receptors. PLoS One. 2014;9:e86770.
36. Sliwa K, van der Meer P, Petrie MC, et al. Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the heart failure association of the European Society of Cardiology study group on peripartum cardiomyopathy. Eur J Heart Fail. 2021;23:527-40.
37. Cowgill JA, Francis SA, Sawyer DB. Anthracycline and peripartum cardiomyopathies. Circ Res. 2019;124:1633-46.
38. Norouzi M, Amiri Z, Ghavami V, Madahali MH, Moradi A, Mosafarkhani E. Investigating the risk factors of cardiomyopathy in pregnant mothers. Int J Cardiol. 2025;419:132696.
39. Sliwa K, van der Meer P, Viljoen C, et al; EURObservational Research Programme. Socio-economic factors determine maternal and neonatal outcomes in women with peripartum cardiomyopathy: a study of the ESC EORP PPCM registry. Int J Cardiol. 2024;398:131596.
40. Cho SH, Leonard SA, Lyndon A, et al. Pre-pregnancy obesity and the risk of peripartum cardiomyopathy. Am J Perinatol. 2021;38:1289-96.
41. Fett JD, Markham DW. Discoveries in peripartum cardiomyopathy. Trends Cardiovasc Med. 2015;25:401-6.
42. Eggleton EJ, McMurrugh KJ, Aiken CE. Maternal pregnancy outcomes in women with cardiomyopathy: a systematic review and meta-analysis. Am J Obstet Gynecol. 2022;227:582-92.
43. Iannaccone G, Graziani F, Kacar P, et al. Diagnosis and management of peripartum cardiomyopathy and recurrence risk. Int J Cardiol Congenit Heart Dis. 2024;17:100530.
44. Safira A, Tjahjadi AK, Adytia GJ, Waitupu A, Sutanto H. Peripartum cardiomyopathy unveiled: etiology, diagnosis, and therapeutic insights. Curr Probl Cardiol. 2024;49:102474.
45. Singh A, Irfan H, Ali T, et al. Precision medicine in peripartum cardiomyopathy: advancing diagnosis and management through genomic and phenotypic integration. Ann Med Surg. 2024;86:4664-7.
46. Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation. 2005;111:2050-5.
47. Fett JD. Earlier detection can help avoid many serious complications of peripartum cardiomyopathy. Future Cardiol. 2013;9:809-16.
48. Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J. 2006;152:509-13.
49. Sliwa K, Förster O, Libhaber E, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J. 2006;27:441-6.
50. Hibbard JU, Lindheimer M, Lang RM. A modified definition for peripartum cardiomyopathy and prognosis based on echocardiography. Obstet Gynecol. 1999;94:311-6.
51. Blauwet LA, Cooper LT. Diagnosis and management of peripartum cardiomyopathy. Heart. 2011;97:1970-81.
52. Goland S, Bitar F, Modi K, et al. Evaluation of the clinical relevance of baseline left ventricular ejection fraction as a predictor of recovery or persistence of severe dysfunction in women in the United States with peripartum cardiomyopathy. J Card Fail. 2011;17:426-30.
53. Mandal D, Mandal S, Mukherjee D, et al. Pregnancy and subsequent pregnancy outcomes in peripartum cardiomyopathy. J Obstet Gynaecol Res. 2011;37:222-7.
54. Honigberg MC, Elkayam U, Rajagopalan N, et al; IPAC Investigators. Electrocardiographic findings in peripartum cardiomyopathy. Clin Cardiol. 2019;42:524-9.
55. Resnik JL, Hong C, Resnik R, et al. Evaluation of B-type natriuretic peptide (BNP) levels in normal and preeclamptic women. Am J Obstet Gynecol. 2005;193:450-4.
56. Tanous D, Siu SC, Mason J, et al. B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol. 2010;56:1247-53.
57. Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy-a Heart Failure Society of America practice guideline. J Card Fail. 2018;24:281-302.
58. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the heart failure association of the European Society of Cardiology study group on peripartum cardiomyopathy. Eur J Heart Fail. 2016;18:1096-105.
59. Cecconi M, De Backer D, Antonelli M, et al. Consensus on circulatory shock and hemodynamic monitoring. task force of the European Society of Intensive Care Medicine. Intensive Care Med. 2014;40:1795-815.
60. Attachaipanich T, Attachaipanich S, Kaewboot K. Efficacy and safety of bromocriptine in peripartum cardiomyopathy: a systematic review and meta-analysis. Int J Cardiol. 2025;427:133105.
61. Fett JD. Caution in the use of bromocriptine in peripartum cardiomyopathy. J Am Coll Cardiol. 2008;51:2083.
62. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al; ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: The task force for the management of cardiovascular diseases during pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:3165-241.
63. Gevaert S, Van Belleghem Y, Bouchez S, et al. Acute and critically ill peripartum cardiomyopathy and ‘bridge to’ therapeutic options: a single center experience with intra-aortic balloon pump, extra corporeal membrane oxygenation and continuous-flow left ventricular assist devices. Crit Care. 2011;15:R93.
64. Rihal CS, Naidu SS, Givertz MM, et al; Society for Cardiovascular Angiography and Interventions (SCAI). 2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care: endorsed by the American Heart Assocation, the Cardiological Society of India, and sociedad Latino Americana de Cardiologia intervencion; affirmation of value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d’intervention. J Am Coll Cardiol. 2015;65:e7-e26.
65. Lameijer H, Aalberts JJJ, van Veldhuisen DJ, Meijer K, Pieper PG. Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review. Thromb Res. 2018;169:123-7.
66. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al; European Society of Gynecology (ESG). ESC guidelines on the management of cardiovascular diseases during pregnancy: the task force on the management of cardiovascular diseases during pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:3147-97.
67. Ersbøll AS, Hedegaard M, Søndergaard L, Ersbøll M, Johansen M. Treatment with oral beta-blockers during pregnancy complicated by maternal heart disease increases the risk of fetal growth restriction. BJOG. 2014;121:618-26.
68. Stergiopoulos K, Lima FV. Peripartum cardiomyopathy-diagnosis, management, and long term implications. Trends Cardiovasc Med. 2019;29:164-73.
69. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022;145:e895-1032.
70. Radakrishnan A, Dokko J, Pastena P, Kalogeropoulos AP. Thromboembolism in peripartum cardiomyopathy: a systematic review. J Thorac Dis. 2024;16:645-60.
71. DeLoughery E, Bannow BS. Anticoagulant therapy for women: implications for menstruation, pregnancy, and lactation. Hematology Am Soc Hematol Educ Program. 2022;2022:467-73.
72. McNamara DM, Elkayam U, Alharethi R, et al. Clinical outcomes for peripartum cardiomyopathy in north America: results of the IPAC study (investigations of pregnancy-associated cardiomyopathy). J Am Coll Cardiol. 2015;66:905-14.
73. Duran N, Günes H, Duran I, Biteker M, Ozkan M. Predictors of prognosis in patients with peripartum cardiomyopathy. Int J Gynaecol Obstet. 2008;101:137-40.
74. Chapa JB, Heiberger HB, Weinert L, Decara J, Lang RM, Hibbard JU. Prognostic value of echocardiography in peripartum cardiomyopathy. Obstet Gynecol. 2005;105:1303-8.
75. Tak BT, Cay S, Pamukcu HE, et al. Prognostic nutritional index as a novel marker for prediction of prognosis in patients with peripartum cardiomyopathy. Medicine. 2020;99:e19524.
76. Hu CL, Li YB, Zou YG, et al. Troponin T measurement can predict persistent left ventricular dysfunction in peripartum cardiomyopathy. Heart. 2007;93:488-90.
77. Li W, Li H, Long Y. Clinical characteristics and long-term predictors of persistent left ventricular systolic dysfunction in peripartum cardiomyopathy. Can J Cardiol. 2016;32:362-8.
78. Damp J, Givertz MM, Semigran M, et al; IPAC Investigators. Relaxin-2 and soluble Flt1 levels in peripartum cardiomyopathy: results of the multicenter IPAC study. JACC Heart Fail. 2016;4:380-8.
79. Lindley KJ, Conner SN, Cahill AG, Novak E, Mann DL. Impact of preeclampsia on clinical and functional outcomes in women with peripartum cardiomyopathy. Circ Heart Fail. 2017;10:e003797.
80. Hoevelmann J, Engel ME, Muller E, et al. A global perspective on the management and outcomes of peripartum cardiomyopathy: a systematic review and meta-analysis. Eur J Heart Fail. 2022;24:1719-36.
81. Briasoulis A, Mocanu M, Marinescu K, et al. Longitudinal systolic strain profiles and outcomes in peripartum cardiomyopathy. Echocardiography. 2016;33:1354-60.
82. Jackson AM, Macartney M, Brooksbank K, et al. A 20-year population study of peripartum cardiomyopathy. Eur Heart J. 2023;44:5128-41.
83. Sliwa K, Jackson A, Viljoen C, et al. Pregnancies in women after peri-partum cardiomyopathy: the global European Society of Cardiology euroobservational research programme peri-partum cardiomyopathy registry. Eur Heart J. 2025;46:1031-40.
84. Phan D, Duan L, Ng A, Shen AY, Lee MS. Characteristics and outcomes of pregnant women with cardiomyopathy stratified by etiologies: a population-based study. Int J Cardiol. 2020;305:87-91.
85. Sliwa K, Petrie MC, Hilfiker-Kleiner D, et al. Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology study group on peripartum cardiomyopathy. Eur J Heart Fail. 2018;20:951-62.
86. Roos-Hesselink JW, Cornette J, Sliwa K, Pieper PG, Veldtman GR, Johnson MR. Contraception and cardiovascular disease. Eur Heart J. 2015;36:1728-34, 1734a.
87. Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776-89.
88. Bright RA, Lima FV, Avila C, Butler J, Stergiopoulos K. Maternal heart failure. J Am Heart Assoc. 2021;10:e021019.
89. Beardmore KS, Morris JM, Gallery ED. Excretion of antihypertensive medication into human breast milk: a systematic review. Hypertens Pregnancy. 2002;21:85-95.
90. Habli M, O'Brien T, Nowack E, Khoury S, Barton JR, Sibai B. Peripartum cardiomyopathy: prognostic factors for long-term maternal outcome. Am J Obstet Gynecol. 2008;199:415.e1-5.
92. Pachariyanon P, Bogabathina H, Jaisingh K, Modi M, Modi K. Long-term outcomes of women with peripartum cardiomyopathy having subsequent pregnancies. J Am Coll Cardiol. 2023;82:16-26.
93. Elkayam U, Tummala PP, Rao K, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med. 2001;344:1567-71.
94. Bozkurt B, Colvin M, Cook J, et al; American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; and Council on Quality of Care and Outcomes Research. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation. 2016;134:e579-646.
95. Karaye KM, Ishaq NA, Sa’idu H, et al. Selenium deficiency as a risk factor for peripartum cardiomyopathy. West Afr J Med. 2024;41:209-214.
96. Karaye KM, Sa’idu H, Balarabe SA, et al. Selenium supplementation in patients with peripartum cardiomyopathy: a proof-of-concept trial. BMC Cardiovasc Disord. 2020;20:457.
97. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128:589-600.
98. Trongtorsak A, Kittipibul V, Mahabir S, et al. Effects of bromocriptine in peripartum cardiomyopathy: a systematic review and meta-analysis. Heart Fail Rev. 2022;27:533-43.
99. Lindley KJ, Verma AK, Blauwet LA. Peripartum cardiomyopathy: progress in understanding the etiology, management, and prognosis. Heart Fail Clin. 2019;15:29-39.
